Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Get Free Report) EVP Charles Wagner, Jr. sold 15,286 shares of the firm’s stock in a transaction that occurred on Thursday, November 12th. The stock was sold at an average price of $547.87, for a total transaction of $8,374,740.82. Following the transaction, the executive vice president owned 31,764 shares in the company, valued at approximately $17,402,542.68. This trade represents a 32.49% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Vertex Pharmaceuticals Stock Performance
VRTX stock traded down $0.81 during trading on Monday, hitting $537.79. The company had a trading volume of 1,199,160 shares, compared to its average volume of 1,392,167. The firm has a market cap of $136.35 billion, a PE ratio of 34.61, a price-to-earnings-growth ratio of 2.85 and a beta of 0.28. The company has a quick ratio of 1.89, a current ratio of 2.34 and a debt-to-equity ratio of 0.17. Vertex Pharmaceuticals Incorporated has a 1-year low of $412.27 and a 1-year high of $568.67. The firm has a 50-day moving average price of $522.37 and a 200-day moving average price of $483.84.
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) last released its earnings results on Monday, November 2nd. The pharmaceutical company reported $4.76 EPS for the quarter, missing the consensus estimate of $4.82 by ($0.06). The firm had revenue of $3.44 billion during the quarter, compared to analyst estimates of $3.42 billion. Vertex Pharmaceuticals had a return on equity of 21.98% and a net margin of 30.70%. The firm’s revenue was up 11.8% on a year-over-year basis. During the same quarter last year, the business posted $4.80 EPS. On average, analysts expect that Vertex Pharmaceuticals Incorporated will post 16.10 earnings per share for the current year.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently made changes to their positions in VRTX. Utah Retirement Systems increased its holdings in shares of Vertex Pharmaceuticals by 0.3% in the third quarter. Utah Retirement Systems now owns 38,725 shares of the pharmaceutical company’s stock valued at $20,246,000 after purchasing an additional 123 shares in the last quarter. Cetera Investment Advisers raised its stake in shares of Vertex Pharmaceuticals by 2.2% in the 3rd quarter. Cetera Investment Advisers now owns 79,791 shares of the pharmaceutical company’s stock valued at $41,716,000 after purchasing an additional 1,684 shares during the period. Elefante Mark B raised its holdings in shares of Vertex Pharmaceuticals by 19.3% in the third quarter. Elefante Mark B now owns 11,078 shares of the pharmaceutical company’s stock valued at $5,792,000 after purchasing an additional 1,793 shares during the last quarter. Empirical Finance LLC lifted its position in Vertex Pharmaceuticals by 2.2% during the 3rd quarter. Empirical Finance LLC now owns 9,180 shares of the pharmaceutical company’s stock worth $4,799,000 after buying an additional 194 shares in the last quarter. Finally, Blue Chip Partners LLC boosted its position in Vertex Pharmaceuticals by 15.8% during the third quarter. Blue Chip Partners LLC now owns 2,757 shares of the pharmaceutical company’s stock valued at $1,441,000 after purchasing an additional 377 shares during the last quarter. 90.96% of the stock is owned by institutional investors.
Analyst Ratings Changes
A number of equities analysts have recently weighed in on the company. Scotiabank boosted their price target on Vertex Pharmaceuticals from $558.00 to $660.00 and gave the stock a “sector outperform” rating in a report on Tuesday, November 3rd. Canaccord Genuity Group lifted their target price on Vertex Pharmaceuticals from $436.00 to $442.00 and gave the company a “hold” rating in a research note on Tuesday, August 4th. Weiss Ratings cut Vertex Pharmaceuticals from a “buy (b)” rating to a “buy (b-)” rating in a research note on Monday, November 9th. UBS Group boosted their price target on shares of Vertex Pharmaceuticals from $615.00 to $640.00 and gave the stock a “buy” rating in a research report on Tuesday, November 3rd. Finally, Rothschild & Co Redburn lifted their target price on shares of Vertex Pharmaceuticals from $570.00 to $580.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, twenty-five have given a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, Vertex Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $596.44.
View Our Latest Report on Vertex Pharmaceuticals
About Vertex Pharmaceuticals
Vertex Pharmaceuticals is a biotechnology company headquartered in Boston, Massachusetts. Founded in 1989, it develops medicines for serious diseases, with a long-standing focus on cystic fibrosis (CF). Vertex’s CF treatments include medicines that target the underlying protein defect, such as Trikafta/Kaftrio, Alyftrek, Kalydeco, Orkambi and Symdeko/Symkevi. The company also markets Journavx, a non-opioid medicine for acute pain, and partnered with CRISPR Therapeutics to develop Casgevy, a gene-editing treatment for sickle cell disease and transfusion-dependent beta thalassemia.
Featured Articles
- Five stocks we like better than Vertex Pharmaceuticals
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
